{"id":10420,"date":"2024-10-28T07:26:12","date_gmt":"2024-10-28T12:26:12","guid":{"rendered":"https:\/\/ibio.org\/?p=10420"},"modified":"2024-10-28T07:26:12","modified_gmt":"2024-10-28T12:26:12","slug":"abbvie-to-acquire-alzheimers-drug-developer-aliada-therapeutics-for-1-4-billion","status":"publish","type":"post","link":"https:\/\/ibio.org\/abbvie-to-acquire-alzheimers-drug-developer-aliada-therapeutics-for-1-4-billion\/","title":{"rendered":"AbbVie to Acquire Alzheimer&#8217;s Drug Developer Aliada Therapeutics for $1.4 Billion"},"content":{"rendered":"<p class=\"whitespace-pre-wrap break-words\">AbbVie <a href=\"https:\/\/news.abbvie.com\/2024-10-28-AbbVie-to-Acquire-Aliada-Therapeutics,-Strengthening-Focus-in-Alzheimers-Disease-and-Neuroscience-Pipeline?utm_campaign=the_readout&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8p_PKpRxp5qNbUD0VHepHd7skT8N-RHjlUaLM_tIn61M6HnhERv4dMqazI2y5NlP48L3D7A2ljKvsdSfWBFQB-XfeNog&amp;_hsmi=331127898&amp;utm_content=331127898&amp;utm_source=hs_email\">announced today<\/a> it will acquire Boston-based Aliada Therapeutics in a $1.4 billion cash deal, expanding its presence in neuroscience and Alzheimer&#8217;s disease research. The acquisition gives AbbVie access to Aliada&#8217;s novel blood-brain barrier crossing technology and its promising Alzheimer&#8217;s drug candidate.<\/p>\n<p class=\"whitespace-pre-wrap break-words\">Aliada&#8217;s lead compound, ALIA-1758, is an antibody therapy currently in Phase 1 clinical trials. The drug targets pyroglutamate amyloid beta, a component of the brain plaques characteristic of Alzheimer&#8217;s disease. What makes ALIA-1758 particularly notable is its use of Aliada&#8217;s proprietary MODEL\u2122 platform, which helps therapeutic compounds cross the blood-brain barrier more effectively.<\/p>\n<p class=\"whitespace-pre-wrap break-words\">&#8220;Many promising CNS-targeted therapies fail to reach late-stage trials due to their inability to cross the blood-brain barrier,&#8221; explained Dr. Michael Ryan, Aliada&#8217;s chief medical officer. &#8220;Our MODEL\u2122 platform addresses this challenge directly.&#8221;<\/p>\n<p class=\"whitespace-pre-wrap break-words\">The technology works by targeting specific receptors (transferrin and CD98) that are abundant in brain blood vessel cells, potentially offering a more efficient way to deliver various types of drugs to the brain, including antibodies and genetic medicines.<\/p>\n<p class=\"whitespace-pre-wrap break-words\">Dr. Roopal Thakkar, AbbVie&#8217;s chief scientific officer, emphasized that neuroscience is a key growth area for the company. &#8220;This acquisition immediately positions us to advance ALIA-1758, a potentially best-in-class disease-modifying therapy for Alzheimer&#8217;s disease,&#8221; he said.<\/p>\n<p class=\"whitespace-pre-wrap break-words\">Aliada, founded in 2021 through investments from Johnson &amp; Johnson, RA Capital Management, and other venture capital firms, has developed its technology based on research originally conducted at Johnson &amp; Johnson.<\/p>\n<p class=\"whitespace-pre-wrap break-words\">The transaction is expected to close in the fourth quarter of 2024, subject to regulatory approvals and standard closing conditions.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie announced today it will acquire Boston-based Aliada Therapeutics in a $1.4 billion cash deal, expanding its presence in neuroscience and Alzheimer&#8217;s disease research. The acquisition gives AbbVie access to Aliada&#8217;s novel blood-brain barrier crossing technology and its promising Alzheimer&#8217;s drug candidate. Aliada&#8217;s lead compound, ALIA-1758, is an antibody therapy currently in Phase 1 clinical [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":10422,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[145,526],"tags":[340,253],"class_list":["post-10420","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-community-news","category-newsbrief","tag-abbvie","tag-alzheimers"],"_links":{"self":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/comments?post=10420"}],"version-history":[{"count":1,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10420\/revisions"}],"predecessor-version":[{"id":10421,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/10420\/revisions\/10421"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media\/10422"}],"wp:attachment":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media?parent=10420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/categories?post=10420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/tags?post=10420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}